Homocysteine Lowering and Cognition in CKD: The Veterans Affairs Homocysteine Study

American Journal of Kidney Diseases

Volumn 54, Issue 3, 2009, Pages 440-449

  Brady, Christopher B ^a,b,c   Gaziano, J Michael ^a,c   Cxypoliski, Roberta A ^a   Guarino, Peter D ^d   Kaufman, James S ^a,b   Warren, Stuart R ^a,e   Hartigan, Pamela ^d   Goldfarb, David S ^f,g   Jamison, Rex L ^h,i  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h VA PALO ALTO HEALTH CARE SYSTEM   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

clinical trial; Cognition; homocysteine; kidney disease

Indexed keywords

HOMOCYSTEINE; PLACEBO; VITAMIN B GROUP;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; AGED; COGNITION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RISK FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VITAMIN B COMPLEX;

EID: 68849097871     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.05.013     Document Type: Article

References (61)

1. Kurella M., Chertow G.M., Luan J., and Yaffe K. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc 52 (2004) 1863-1869
2. Kurella M., Yaffe K., Shlipak M.G., Wenger N.K., and Chertow G.M. Chronic kidney disease and cognitive impairment in menopausal women. Am J Kidney Dis 45 (2005) 66-76
3. Kurella Tamura M., Wadley V., Yaffe K., et al. Kidney function and cognitive impairment in US adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis 52 (2008) 227-234
4. Madero M., Gul A., and Sarnak M.J. Cognitive function in chronic kidney disease. Semin Dial 21 (2008) 29-37
5. Murray A.M., Tupper D.E., Knopman D.S., et al. Cognitive impairment in hemodialysis patients is common. Neurology 67 (2006) 216-223
6. Pereira A.A., Weiner D.E., Scott T., and Sarnak M.J. Cognitive function in dialysis patients. Am J Kidney Dis 45 (2005) 448-462
7. Seliger S.L., Siscovick D.S., Stehman-Breen C.O., et al. Moderate renal impairment and risk of dementia among older adults: The Cardiovascular Health Cognition Study. J Am Soc Nephrol 15 (2004) 1904-1911
8. Weiner D.E. The cognition-kidney disease connection: Lessons from population-based studies in the United States. Am J Kidney Dis 52 (2008) 201-204
9. Bostom A.G., Shemin D., Verhoef P., et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 17 (1997) 2554-2558
10. Friedman A.N., Bostom A.G., Selhub J., Levey A.S., and Rosenberg I.H. The kidney and homocysteine metabolism. J Am Soc Nephrol 12 (2001) 2181-2189
11. Jungers P., Massy Z.A., Nguyen Khoa T., et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol Dial Transplant 12 (1997) 2597-2602
12. Dufouil C., Alperovitch A., Ducros V., and Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol 53 (2003) 214-221
13. Elias M.F., Sullivan L.M., D'Agostino R.B., et al. Homocysteine and cognitive performance in the Framingham offspring study: Age is important. Am J Epidemiol 162 (2005) 644-653
14. McCaddon A., Hudson P., Davies G., Hughes A., Williams J.H.H., and Wilkinson C. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 12 (2001) 309-313
15. Morris M.S., Jacques P.F., Rosenberg I.H., and Selhub J. Hyperhomocysteinemia associated with poor recall in the Third National Health and Nutrition Examination Survey. Am J Clin Nutr 73 (2001) 927-933
16. Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., and Ueland P.M. Folate, vitamin B-12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55 (1998) 1449-1455
17. Haan M.N., Miller J.W., Aiello A.E., et al. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: Results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr 85 (2007) 511-517
18. Seshadri S., Beiser A., Selhub J., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346 (2002) 476-483
19. 12, and folic acid supplementation and cognitive function: A systematic review of randomized trials. Arch Intern Med 167 (2007) 21-30
20. Jamison R.L., Hartigan P., Gaziano J.M., et al. Design and statistical issues in the Homocysteinemia in Kidney and End Stage Renal Disease (HOST) study. Clin Trials 1 (2004) 451-460
21. Jamison R.L., Hartigan P., Kaufman J.S., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA 298 (2007) 1163-1170
22. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
23. Griva K., Newman S.P., Harrison M.J., et al. Acute neuropsychological changes in hemodialysis and peritoneal dialysis patients. Health Psychol 22 (2003) 570-578
24. Welsh K.A., Breitner J.C., and Magruder-Habib K.M. Detection of dementia in the elderly using telephone screening of cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 6 (1993) 103-110
25. Crooks V.C., Clark L., Petitti D.B., Chui H., and Chiu V. Validation of multi-stage telephone-based identification of cognitive impairment and dementia. BMC Neurol 5 (2005) 8
26. Gallo J.J., and Breitner J.C.S. Alzheimer's disease in the NAS-NRC Registry of ageing twin veterans: IV. Performance characteristics of a two-stage telephone screening procedure for Alzheimer's dementia. Psychol Med 25 (1995) 1211-1219
27. Jarvenpaa T., Rinne J.O., Raiha I., et al. Characteristics of two telephone screens for cognitive impairment. Dement Geriatr Cogn Disord 13 (2002) 149-155
28. Plassman B.L., Newman T.T., Welsh K.A., et al. Properties of the telephone interview for cognitive status: Application in epidemiological and longitudinal studies. Neuropsychiatry Neuropsychol Behav Neurol 7 (1994) 235-241
29. Wechsler D. Wechsler Adult Intelligence Scale. (ed 3) (1997), Psychological Corp, San Antonio, CA
30. Lezak M.D. Neuropsychological Assessment (1995), Oxford University, New York, NY
31. Yesavage J.A., and Brink T.L. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 17 (1983) 37-49
32. Pliskin N.H., Kiolbasa T.A., Hart R.P., and Umans J.G. Neuropsychological function in renal disease and its treatment. In: Tarter R.E., and Butters M. (Eds). Medical Neuropsychology. (ed 2) (2001), Klumer Academic/Plenum, New York, NY 107-126
33. Montorio I., and Izal M. The Geriatric Depression Scale: A review of its development and utility. Int Psychogeriatr 8 (1996) 103-112
34. Chelune G.J., Naugle R.I., Lueders H., et al. Individual change after epilepsy surgery: Practice effects and base-rate information. Neuropsychology 7 (1993) 41-52
35. Collie A., Maruff P., Makdissi M., McStephen M., Darby D.G., and McCrory P. Statistical procedures for determining the extent of cognitive change following concussion. Br J Sports Med 38 (2004) 273-278
36. Hensel A., Angermeyer M.C., and Riedel-Heller S.G. Measuring cognitive change in older adults: Reliable change indices for the Mini-Mental State Examination. J Neurol Neurosurg Psychiatry 78 (2007) 1298-1303
37. Aisen P.S., Schneider L.S., Sano M., et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial. JAMA 300 (2008) 1774-1783
38. Kang J.H., Cook N., Manson J., Buring J.E., Albert C.M., and Grodstein F. A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. Am J Clin Nutr 88 (2008) 1602-1610
39. McMahon J.A., Green T.J., Skeaff C.M., Knight R.G., Mann J.I., and Williams S.M. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 354 (2006) 2764-2772
40. Stott D.J., MacIntosh G., Lowe G.D., et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr 82 (2005) 1320-1326
41. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291 (2004) 565-575
42. Durga J., van Boxtel M.P., Schouten E.G., et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. Lancet 369 (2007) 208-216
43. Nulsen R.S., Yaqoob M.M., Mahon A., Stoby-Fields M., Kelly M., and Varagunam M. Prevalence of cognitive impairment in patients attending pre-dialysis clinic. J Ren Care 34 (2008) 121-126
44. Kutlay S., Nergizoglu G.k., Duman N., et al. Recognition of neurocognitive dysfunction in chronic hemodialysis patients. Ren Fail 23 (2001) 781-787
45. Sehgal A.R., Grey S.F., DeOreo P.B., and Whitehouse P.J. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis 30 (1997) 41-49
46. Tyrrell J., Paturel L., Cadec B., Capezzali E., and Poussin G. Older patients undergoing dialysis treatment: Cognitive functioning, depressive mood and health-related quality of life. Aging Ment Health 9 (2005) 374-379
47. Monk R.D., and Bennett D.A. Reno-cerebrovascular disease?. The incognito kidney in cognition and stroke. Neurology 67 (2006) 196-198
48. Elias M.F., D'Agostino R.B., Elias P.K., and Wolf P.A. Neuropsychological test performance, cognitive functioning, blood pressure and age: The Framingham Heart Study. Exp Aging Res 21 (1995) 369-391
49. Elias M.F., Elias P.K., Robbins M.A., Wolf P.A., and D'Agostino R.B. Cardiovascular risk factors and cognitive functioning: An epidemiological perspective. In: Waldstein S.R., and Elias M.F. (Eds). Neuropsychology of Cardiovascular Disease (2001), Erlbaum, Mahwah, NJ 83-104
50. Ryan C.M. Diabetes-associated cognitive dysfunction. In: Waldstein S.R., and Elias M.F. (Eds). Neuropsychology of Cardiovascular Disease (2001), Erlbaum, Mahwah, NJ 61-82
51. Waldstein S.R., and Katzel L.I. Hypertension and cognitive function. In: Waldstein S.R., and Elias M.F. (Eds). Neuropsychology of Cardiovascular Disease (2001), Erlbaum, Mahwah, NJ 15-36
52. Grodstein F., Kang J.H., Glynn R.J., Cook N.R., and Gaziano J.M. A randomized trial of beta carotene supplementation and cognitive function in men: The Physicians' Health Study II. Arch Intern Med 167 (2007) 2184-2190
53. Grady D., Yaffe K., Kristof M., Lin F., Richards C., and Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: The Heart and Estrogen/progestin Replacement Study. Am J Med 113 (2002) 543-548
54. Kurella M., Chertow G.M., Fried L.F., et al. Chronic kidney disease and cognitive impairment in the elderly: The Health, Aging, and Body Composition Study. J Am Soc Nephrol 16 (2005) 2127-2133
55. Altmann P., Barnett M.E., and Finn W.F. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 71 (2007) 252-259
56. Colsher P.L., and Wallace R.B. Longitudinal application of cognitive function measures in a defined population of community-dwelling elders. Ann Epidemiol 1 (1991) 215-230
57. Sliwinski M., and Buschke H. Cross-sectional and longitudinal relationships among age, cognition, and processing speed. Psychol Aging 14 (1999) 18-33
58. Small B.J., Basun H., and Backman L. Three-year changes in cognitive performance as a function of apolipoprotein E genotype: Evidence from very old adults without dementia. Psychol Aging 13 (1998) 80-87
59. Brady C.B., Spiro A., McGlinchey-Berroth R., Milberg W., and Gaziano J.M. Stroke risk predicts verbal fluency decline in healthy older men: Evidence from the Normative Aging Study. J Gerontol Psychol Sci 56B (2001) P340-P346
60. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials. Am Heart J 151 (2006) 282-287
61. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 43 suppl 1 (2004) S14-S290